09.24.12
Rick Hancock has been appointed chief executive officer of Althea Technologies. In addition, Chris Duffy has been named senior vice president of operations and E.J. Brandreth was named senior vice president of Quality and Regulatory.
Mr. Hancock joined the company in 1998 and was previously president of Althea; he will retain the title of president in his new role. He has 30 years of Biotechnology industry experience having held positions at Hybritech/Eli Lilly, Genetics Institute, and The Immune Response Corp. In his new role, Mr. Hancock will play a stronger role in the development of strategies to continue Althea's growth efforts.
Mr. Duffy joined the company 12 years ago and has been instrumental in the development of the company. He has more than 26 years of experience in the biotech industry managing Biopharmaceutical development and sterile manufacturing operations. Under his leadership, Althea's Fill Finish group has grown and transitioned from a clinical to a commercial operation. Mr. Duffy will employ his expertise in science and business in his new role.
Mr. Brandreth has more than 20 years of experience in the biotechnology and pharmaceutical industries, having managed numerous agency inspections and led the Process Validation programs for five CBER /EMEA product launches. Additionally, Mr. Brandreth serves on Biocom’s FDA Committee, Interphex's Advisory Board, and PDA's Biotech Advisory Board as Chairman. Prior to joining the company, Mr. Brandreth was with Favrille and Biomarin where he supported a variety of clinical products and launched two commercial products.
"I am very pleased to announce the promotions of Rick Hancock, Chris Duffy and E.J. Brandreth," said Dr. Magda Marquet, co-founder and co-chairman of Althea Technologies. "These individuals truly embody the spirit of Althea by providing, through their leadership and dedication, unmatched service to the customer with uncompromised quality. I am confident each executive will play a crucial role in leading Althea to continued future growth."
Mr. Hancock joined the company in 1998 and was previously president of Althea; he will retain the title of president in his new role. He has 30 years of Biotechnology industry experience having held positions at Hybritech/Eli Lilly, Genetics Institute, and The Immune Response Corp. In his new role, Mr. Hancock will play a stronger role in the development of strategies to continue Althea's growth efforts.
Mr. Duffy joined the company 12 years ago and has been instrumental in the development of the company. He has more than 26 years of experience in the biotech industry managing Biopharmaceutical development and sterile manufacturing operations. Under his leadership, Althea's Fill Finish group has grown and transitioned from a clinical to a commercial operation. Mr. Duffy will employ his expertise in science and business in his new role.
Mr. Brandreth has more than 20 years of experience in the biotechnology and pharmaceutical industries, having managed numerous agency inspections and led the Process Validation programs for five CBER /EMEA product launches. Additionally, Mr. Brandreth serves on Biocom’s FDA Committee, Interphex's Advisory Board, and PDA's Biotech Advisory Board as Chairman. Prior to joining the company, Mr. Brandreth was with Favrille and Biomarin where he supported a variety of clinical products and launched two commercial products.
"I am very pleased to announce the promotions of Rick Hancock, Chris Duffy and E.J. Brandreth," said Dr. Magda Marquet, co-founder and co-chairman of Althea Technologies. "These individuals truly embody the spirit of Althea by providing, through their leadership and dedication, unmatched service to the customer with uncompromised quality. I am confident each executive will play a crucial role in leading Althea to continued future growth."
